JPRN-UMIN000010405已完成未知
Study of the antibody titer by Influenza vaccination in Rheumatoid Arthritis patients treated with MTX and Biological agents - Influenza Biologics Study
agoya Medical Center, National Hospital Organization in JAPA0 个研究点目标入组 170 人开始时间: 2013年4月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Study of the Influenza vaccine immune response using PMMA dialyzer.JPRN-UMIN000019455Oita University Hospital Blood purification center120
已完成
不适用
Study of the Influenza vaccine immune response using PMMA dialyzer.End-stage renal disease requiring hemodialysisJPRN-UMIN000015853Oita naika clinic50
终止
不适用
Boosting influenza vaccine responses in the elderly using a brief bout of exerciseAdvanced ageInfluenza vaccine responsesInflammatory and Immune System - Normal development and function of the immune systemACTRN12611001119987niversity of Sydney96
进行中（未招募）
1 期
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003055-30-ESGilead Sciences, Inc.22
进行中（未招募）
1 期
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003055-30-CZGilead Sciences, Inc.22